[Immune-related severe pneumonia: A case report].

Area of Science:

• Oncology
• Immunology
• Pulmonology

Background:

• Immune checkpoint inhibitors (ICIs) are vital in cancer therapy, improving outcomes for advanced cases.
• However, ICI use increases the risk of immune-related adverse events (irAEs), including severe pneumonia, myocarditis, and encephalitis, posing significant clinical challenges.
• Understanding irAE mechanisms and management is critical for optimizing cancer treatment.

Purpose of the Study:

• To report a case of severe immune checkpoint inhibitor-associated pneumonia (ICI-AP).
• To review clinical features, diagnostic methods, and treatment strategies for ICI-AP.
• To propose potential biomarkers for guiding biological agent therapy in ICI-AP.

Main Methods:

• Case report of severe ICI-AP.
• Review of relevant clinical guidelines and literature.
• Analysis of diagnostic indicators including blood cell ratios, bronchoalveolar lavage fluid, bronchoscopy, and lung biopsy.
• Evaluation of treatment approaches including glucocorticoids and biological agents.

Main Results:

• Increased neutrophil-to-lymphocyte and eosinophil-to-lymphocyte ratios may indicate irAEs.
• Bronchoalveolar lavage, bronchoscopy, and biopsy aid in diagnosing ICI-AP.
• Prompt glucocorticoid therapy is essential; biological agents and immunoglobulin may be beneficial but require further study.
• Serum inflammatory markers (IL-6, TNF-α, CRP) may guide biological agent initiation.

Conclusions:

• ICI-AP requires consideration in patients with respiratory symptoms during immunotherapy.
• Effective management involves timely immunosuppressive therapy, potentially augmented by biological agents.
• Further research is needed to clarify indications for biological agents and mitigate infection risks associated with immunosuppression.